solution for infusion
Sponsors
Seelos Therapeutics Inc., Universite De Liege, CHU De Liege, Bristol-Myers Squibb Services Unlimited Company, Grifols Therapeutics LLC
Conditions
Advanced Renal Cell Carcinoma with Intermediate- or Poor-Risk FactorsChronic inflammatory demyelinating polyradiculoneuropathy (CIDP)Disorder of ConsciousnessMultiple MyelomaSecondary Antibody Deficiency Associated with Chronic Lymphocytic LeukemiaSpinocerebellar Ataxia type-3 (SCA3)or Non-Hodgkin Lymphomasevere brain injury
Phase 2
A DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED TRIAL TO ASSESS SAFETY AND EFFICACY OF SLS-005 (TREHALOSE INJECTION, 90.5 MG/ML FOR INTRAVENOUS INFUSION) FOR THE TREATMENT OF ADULTS WITH SPINOCEREBELLAR ATAXIA
CompletedCTIS2022-501004-10-00
Start: 2023-01-30End: 2024-02-12Target: 58Updated: 2023-03-10
Treating severe brain-injured patients with apomorphine : a behavioural and neuroimaging study
RecruitingCTIS2023-504631-40-01
Start: 2018-09-05Target: 102Updated: 2025-07-24
Phase 3
A Phase 3b, Randomized, Double-blind Study of Nivolumab Combined with Ipilimumab versus Nivolumab Monotherapy for Patients with Previously Untreated Advanced Renal Cell Carcinoma and Intermediate- or Poor-Risk Factors
Active, not recruitingCTIS2023-508264-29-00
Start: 2019-06-11Target: 254Updated: 2025-12-05
An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics and Safety of Xembify versus Gamunex-C in Participants with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Not yet recruitingCTIS2025-522165-30-00
Target: 6Updated: 2026-07-07
An Open-label, Multi-Center, Single-arm Prospective Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex®-C plus Standard Medical Treatment to Prevent Infections in Participants with Secondary Antibody Deficiency Associated with Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma (Sigma).
Not yet recruitingCTIS2026-526803-31-00
Target: 31Updated: 2026-09-15